COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2​ = 0.00; I​2​ = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.43-0.86]14/7220/7339% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies45%0.55 [0.40-0.77]16/14831/14345% improvement5 bromhexine COVID-19 studiesc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 3.46Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]0/395/39Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]48 (n)52 (n)Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementAll studies87%0.13 [0.01-1.23]0/875/9187% improvement2 bromhexine COVID-19 mortality resultsc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.78Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)82%0.18 [0.04-0.77]2/3911/39Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment82%0.18 [0.04-0.77]2/3911/3982% improvementAll studies82%0.18 [0.04-0.77]2/3911/3982% improvement1 bromhexine COVID-19 ICU resultc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 2.32Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Mikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies80%0.20 [0.01-3.97]0/252/2580% improvement1 bromhexine COVID-19 hospitalization resultc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.06Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies85%0.15 [0.03-0.92]0/1127/11685% improvement3 bromhexine COVID-19 serious outcomesc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 2.06Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Tolouian (RCT)-75%1.75 [1.13-2.71]29/4818/52Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment-75%1.75 [1.13-2.71]29/4818/52-75% improvementAll studies-75%1.75 [1.13-2.71]29/4818/52-75% improvement1 bromhexine COVID-19 case resultc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 2.49Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Mareev (RCT)87%0.13 [0.01-2.25]0/173/13Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment87%0.13 [0.01-2.25]0/173/1387% improvementMikhaylov (RCT)71%0.29 [0.07-1.24]2/257/25Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%PrEP71%0.29 [0.07-1.24]2/257/2571% improvementAll studies76%0.24 [0.07-0.89]2/4210/3876% improvement2 bromhexine COVID-19 viral clearance resultsc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 2.13Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2​ = 0.00; I​2​ = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.43-0.86]14/7220/7339% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies45%0.55 [0.40-0.77]16/14831/14345% improvement5 bromhexine COVID-19 Randomized Controlled Trialsc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 3.46Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]0/395/39Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]48 (n)52 (n)Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementAll studies87%0.13 [0.01-1.23]0/875/9187% improvement2 bromhexine COVID-19 RCT mortality resultsc19bromhexine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.78Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2​ = 0.00; I​2​ = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.43-0.86]14/7220/7339% improvementAll studies50%0.50 [0.29-0.85]16/12329/11850% improvement4 bromhexine COVID-19 peer reviewed trialsc19bromhexine.com Aug 29, 2021Tau​2​ = 0.06; I​2​ = 9.9%; Z = 2.53Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlAnsarin (RCT)89%0.11 [0.01-0.84]ventilation1/399/39Ansarin (RCT)82%0.18 [0.04-0.77]ICU2/3911/39Li (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Li (RCT)50%0.50 [0.09-2.73]oxygen2/122/6Mareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Mareev (RCT)87%0.13 [0.01-2.25]viral+0/173/13Tolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tolouian (RCT)76%0.24 [0.01-7.69]no improv.48 (n)52 (n)Tolouian (RCT)-75%1.75 [1.13-2.71]cases29/4818/52Mikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Mikhaylov (RCT)91%0.09 [0.01-1.56]symp. case0/255/25Mikhaylov (RCT)71%0.29 [0.07-1.24]viral+2/257/25bromhexine COVID-19 outcomesc19bromhexine.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home